BerGenBio

Share Issue/Capital Change • May 22, 2023

BerGenBio ASA: Annual general meeting held

BerGenBio ASA: Annual general meeting held

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN CANADA,

JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH

RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES

NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Bergen 22 May 2023. Reference is made to the stock exchange announcements

published by BerGenBio ASA (the "Company") on 25 April 2023 and 20 May 2023

regarding a proposed partially underwritten rights issue of shares with

preferential rights for existing shareholders in the Company (the "Rights

Issue").

The annual general meeting of the Company has today, on 22 May 2023, approved

all items as proposed by the Board of Directors including the Rights Issue and

the issuance of warrants. The minutes from the annual general meeting are

enclosed hereto and will also be available on the Company's

website (https://www.bergenbio.com/investors/general-meetings/), in the

Investor/General meeting section.

The full terms and conditions for the Rights Issue will be included in a

prospectus, which will be published prior to the commencement of the

subscription period for the Rights Issue. The subscription period is expected to

take place from 30 May 2023 09:00 hours (CEST) to 13 June 2023 at 16.30 (CEST).

Carnegie AS and Arctic Securities AS are acting as managers (the "Managers") in

the Rights Issue. Advokatfirmaet Thommessen AS is acting as legal advisor to the

Company in connection with the Rights Issue.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

For information about the Rights Issue please contact the Managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.